ESMO – In an interim analysis presented at ESMOBreast24 of atezolizumab and sacituzumab in locally advanced or metastatic triple-negative breast cancer

ESMO shared a post on LinkedIn:

“In an interim analysis presented at ESMOBreast24, first-line treatment with the combination of the PD-L1 inhibitor atezolizumab and sacituzumab govitecan showed a higher objective response rate compared to control in patients with previously untreated PD-L1 positive locally advanced or metastatic triple-negative breast cancer.”

Read further.
Source: ESMO/LinkedIn